- All categories
- Biological Sciences
- Medicine, Human Health
- Biology / Biotechnology
- Genome Research
- Bioinformatics Technology
- Gene Expression, Proteom Research Technology
- Population genetics Technology
- Micro- and Nanotechnology related to Biological sciences
- Industrial Biotechnology
- E-Health
- Communications
- Computer related
- Electronics Related Market
- Genetic Engineering / Molecular Biology
- Medical Health related
- Energy Market
- Consumer related
- Industrial Products
- Other
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Big-data Computational Tool for Patient-Specific Cancer TherapyCluster7 Cluster8 From big data analysis to personalized medicine in cancer: towards the development of a computational tool for the rational design of patient-specific combination therapy. Project ID : 10-2016-4322
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Bi-Functional Coating for the Prevention of the Infection of Dental ImplantsSelf-assembly of fluorine-capped moieties for prevention of biofilms Keywords: self-assembly, dental, dentistry, biolfilm, disruption Project ID : 9-2015-3142
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Computational Algorithm to Identify Drug Candidates for Liposomal ReformulationModeling structural drug descriptors for loading and leakage properties of liposomal drugs for the rational identification of new liposomal drug candidates. Project ID : 6-2016-4303 Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
A New Diagnostic Tool to Diagnose and Monitor IBD Using Clock Gene ExpressionA New Diagnostic Tool to Diagnose and Monitor IBD Using Clock Gene Expression Project ID : 8-2018-4562 Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Pro-Nano Lipospheres: as Oral Delivery Platform for Lipophilic DrugsCluster9 oral dispersible concentrate preparation for improving the bioavailability and distribution of lipidic drugs that are substrates of first pass intestinal metabolism and/or are substrates of Pgp efflux. Thus, the formulation elevates the amount of drug that reach the systemic blood circulation and reduces the variability in the oral absorption properties. Project ID : 6-2008-2126
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
New CNS-active Carbamate Derivatives As An Anti-Epileptic DrugNew CNS-active carbamate derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide with a broad potent antiepileptic activity Project ID : 6-2017-4419
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Intranasal Delivery of Biodegradable Neuropeptide NanoparticlesCluster9 Project ID : 6-2014-3054
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Small Molecules Antagonists Of Toll Like Receptor 9 (TLR9) For The Treatment Of Inflammatory ConditionsToll-like receptors, receptors of the innate immunity, play a critical role in the development of many pathological states, in acute and chronic inflammatory processes. Therefore, TLRs represent a new direction for immunotherapy. In order to discover novel ligands interacting with TLRs, Iterative Stochastic Elimination, an innovative beyond-state-of the-art in Silico method for predicting the chances of molecular bioactivity were employed (HUJI IDR). The most promising drug candidates were verified by a cell-based test-system (Fraunhofer IGB) that allows TLR antagonists/agonist to be identified in a reporter gene assay. The ISE process in addition with the assay lead to novel immune modulating therapeutics Project ID : 6-2015-3128
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Oral Delivery Platform for Lipophilic drugs based on Pro-Nano LipospheresCluster9 Dispersible Concentrate Lipospheres for the Delivery of Agents (PNL) Project ID : 6-2017-4492
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
VitaLunga: Novel Oral Drug-Candidate to Prevent Age-Related Degenerative DiseasesBriefly, Some of the degenerative diseases associated with aging (such as Parkinson's Disease, Alzheimer's Dis., Congestive heart failure and more) are caused by decrease in the removal of defective mitochondria; a quality-control process known as mitophagy. The current technology/concept will enable the restoration of mitophagy efficiency, thereby prevent the evolvement of age-related degenerative diseases. As such, it can be used as a treatment; which is a major medically unmet need. The concept: Spermidine (Spd) is a natural polyamine regulating important and diverse physiological processes such as cell growth, cell proliferation, and programmed cell death. The concentration of Spd is decreasing with age in mammals hence it was suggested to adapt a dietary supplementation of Spd to compensate for the natural loss with age and thus support healthy aging. However, the usefulness of Spd as a drug is limited because it can be degraded by gut-associated bacteria and its excessive accumulation inside mammalian cells can result in toxic product formation. And this is exactly where the 6443 (Novel small molecules that facilitate mitophagy ) kicks in. the team suggests to synthesis parallel molecules that mimic this MOA or at least by applying them you receive the same effect of restoration. As of today, several applications have been submitted lately by the group in order to demonstrate the superiority of healthspan of these novel set of stable polyamine-like compounds (compared to native Spd),. Current status: the research was funded by the HUJI funds (קרן המחקר לגימלאים ) resulting with a preliminary findings as specified below. In addition, pre-proposal already sent to the Israeli Ministry of Science and similar. One will be soon submitted to ERC PoC Grant. Based on Ariela, the team would like to have FTO and mainly being able to speak this notion. Conclusion: Following Tami’s email, a conversation I had with Ariela and the materials handed by the researchers it is not possible to review the technology/matured concept further due to lack of information/data. The studied as conducted so far were based on in vivo exp., with Caenorhabditis elegans nematode, which is extensively used as a model organism. The goal was to explore the potency of five compounds as mitophagy-inducers using imaging experiments. The researchers identified successfully two compounds that induced mitophagy (MAC1* and MAC4*) where MAC4 was superior to MAC1 and both Project ID : 6-2018-4576 Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Personalizing Risk Assessment and Treatment Decisions in CancersCluster8 A unified method for the diagnosis and treatment of cancer based on the Expression of the Cancer Tetis Antigen gene Family in Individuals. CTA genes are very active during cellular differentiation and growth and non-active otherwise. The biopsy is beeing tested. Big database. Project ID : 19-2016-4283 Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
A New Paradigm For the Treatment of Diabetes by Induction of Cellular SenescenceENHANCEMENT OF GLUCOSE-STIMULATED INSULIN SECRETION BY CELLS THROUGH INDUCTION OF CELLULAR SENESCENCE Project ID : 6-2016-4284
Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Repurposing of an Approved Drug to Increase NKp30 Ligands for Cancer ImmunotherapyTHE USE OF “INTEGRATED STRESS RESPONSE” ACTIVATORS FOR ENHANCING B7H6-TRAGETED TREATMENTS Project ID : 6-2018-4573 Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
A Method for Generating Herbicide Resistant Plants"herbicide encapsulation by ligand binding proteins to induce herbicide-resistant in crops" Project ID : 21-2016-4387 Yissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew UniversityYissum - Research Development Company of the Hebrew University
Technology Transfer Office
View ProfileYissum - Research Development Company of the Hebrew University posted this:
Targeted Drug Delivery by Cathepsin Nanofiber SubstratesCluster8 Cluster9 Cathepsin Nanofiber Substrates as Potential Agent for Targeted Drug Delivery Project ID : 6-2017-4395
